This comprehensive review analyzes androgenetic alopecia treatments, discussing the mechanisms, costs, efficacy, and safety of FDA-approved drugs like minoxidil and finasteride, as well as newer non-FDA-approved options that have shown effectiveness across various studies.
6 citations
,
May 2020 in “JAMA Ophthalmology” This study suggests that the use of 5α-reductase inhibitors in men may be associated with macular abnormalities, characterized by cystoid changes and foveal cavitation, potentially progressing to more severe defects.
29 citations
,
April 2019 in “BMJ. British medical journal” This study concluded that men with benign prostatic hyperplasia receiving steroid 5α-reductase inhibitors, such as dutasteride or finasteride, have a higher risk of developing new onset type 2 diabetes compared to those taking tamsulosin.
7 citations
,
October 2017 in “Urologic Oncology: Seminars and Original Investigations” This meta-analysis found that male pattern baldness is associated with an increased risk of aggressive prostate cancer and benign prostatic hyperplasia.
111 citations
,
June 2015 in “Age and Ageing” This study classified dutasteride, fesoterodine, and finasteride as beneficial for older or frail elderly patients, while suggesting caution or avoidance of α-blockers and antimuscarinics in this group.
12 citations
,
June 2013 in “The Prostate” This study found that dutasteride more effectively inhibited androgen receptor signaling and reduced cell growth compared to finasteride in prostate cancer cell models, with varying sensitivities across different cell lines.
408 citations
,
May 2004 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” This study found that dutasteride more effectively reduced serum dihydrotestosterone levels than finasteride in patients with benign prostatic hyperplasia.
20 citations
,
January 2004 in “PubMed” This review discusses the pharmacologic effects, safety, and efficacy of dutasteride and finasteride for BPH, finding similar clinical benefits but greater DHT reduction with dutasteride and reports no new trial results.